Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
We use our state-of-the-art dedicated workflow for designing focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
Q9H808
UPID:
TLE6_HUMAN
Alternative names:
-
Alternative UPACC:
Q9H808; J3KMZ1
Background:
Transducin-like enhancer protein 6 plays a pivotal role in cellular processes, including spermatogonia proliferation and cortical neuron differentiation. It functions by regulating cell cycle genes and acting as a transcriptional corepressor. Additionally, as part of the subcortical maternal complex, it is crucial for early embryonic cell divisions and mitotic spindle formation.
Therapeutic significance:
The protein's involvement in oocyte/zygote/embryo maturation arrest 15, a rare cause of female primary infertility, highlights its potential as a target for therapeutic intervention. Understanding the role of Transducin-like enhancer protein 6 could open doors to potential therapeutic strategies.